Moleculin Receives Approval from the UK’s Medicines and Healthcare Merchandise Regulatory Company (MHRA) for Protocol Modification to Part 1a Scientific Trial of WP1122 for the Remedy of COVID-19
– Dosing for first-in-human Part 1a research to judge security and pharmacokinetics of WP1122 in